Weekly Research Analysts’ Ratings Changes for Mersana Therapeutics (MRSN)

Mersana Therapeutics (NASDAQ: MRSN) has recently received a number of price target changes and ratings updates:

  • 4/16/2018 – Mersana Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 4/7/2018 – Mersana Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company’s product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States. “
  • 3/29/2018 – Mersana Therapeutics was given a new $33.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 3/28/2018 – Mersana Therapeutics had its “outperform” rating reaffirmed by analysts at Leerink Swann.
  • 3/23/2018 – Mersana Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company’s product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States. “
  • 3/22/2018 – Mersana Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $20.00 price target on the stock. According to Zacks, “Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company’s product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States. “
  • 3/19/2018 – Mersana Therapeutics was downgraded by analysts at JPMorgan Chase from an “overweight” rating to a “neutral” rating. They now have a $23.00 price target on the stock.
  • 3/19/2018 – Mersana Therapeutics was given a new $33.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 3/2/2018 – Mersana Therapeutics was given a new $33.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.

Shares of NASDAQ:MRSN traded up $0.24 during midday trading on Tuesday, hitting $17.05. 67,650 shares of the stock traded hands, compared to its average volume of 125,423. Mersana Therapeutics Inc. has a one year low of $12.45 and a one year high of $21.01. The company has a market cap of $383.81 and a price-to-earnings ratio of -5.30.

How to Become a New Pot Stock Millionaire

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings results on Wednesday, March 28th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.13). The company had revenue of $3.26 million for the quarter, compared to the consensus estimate of $4.22 million. equities research analysts expect that Mersana Therapeutics Inc. will post -2.53 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in MRSN. ArrowMark Colorado Holdings LLC raised its stake in Mersana Therapeutics by 88.4% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 899,773 shares of the company’s stock worth $14,783,000 after buying an additional 422,062 shares in the last quarter. BlackRock Inc. raised its stake in Mersana Therapeutics by 118.9% in the fourth quarter. BlackRock Inc. now owns 577,299 shares of the company’s stock worth $9,485,000 after buying an additional 313,516 shares in the last quarter. Allianz Asset Management GmbH bought a new position in Mersana Therapeutics in the third quarter worth about $1,419,000. Vanguard Group Inc. bought a new position in Mersana Therapeutics in the second quarter worth about $1,048,000. Finally, Goldman Sachs Group Inc. bought a new position in Mersana Therapeutics in the fourth quarter worth about $247,000. 75.43% of the stock is owned by institutional investors.

Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.

Receive News & Ratings for Mersana Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply